E. G. Flores

DNA methylation patterns as molecular biomarkers: an overview in colorectal cancer

P. Álvarez, C. Melguizo, G. Perazzoli, 2018 .

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

E. G. Flores, C. G. Castro, Joan Maurel Santasusana, 2010 .

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Biochemotherapy in the treatment of metastatic melanoma in selected patients.

E. G. Flores, J. Bautista, Juan Ramón Delgado Pérez, 2009 .

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

F. Rivera, R. López, C. Grávalos, 2018, European journal of cancer.

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

R. López, R. García-Carbonero, E. Díaz-Rubio, 2019, Journal of Clinical Oncology.